BIOVIC B — Biovica International AB Share News
0.000.00%
Last trade - 00:00- SEK88.74m
- SEK43.18m
- SEK13.38m
Brief: Biovica Resolves On Rights Issue Of About SEK 148 Mln
Brief: Biovica International Q1 Operating Loss Widens To SEK 20.7 Mln
Brief: Biovica Receives FDA Approval For DiviTumTKa
Brief: Biovica CFO Resigns
Brief: Biovica: Positive Divitum®TKa Results Published In Npj Breast Cancer
Brief: Biovica International Q3 Oper Loss Widens To SEK 14.4 Mln
Brief: Biovica To Establish Its Own US CLIA Lab In California
Brief: Biovica International Q2 Oper Loss Widens To SEK 14.3 Mln
Brief: Biovica International: Divitumtka Results From Bioitalee Study Presented At Esmo
Brief: Biovica Provides Update On FDA Application Process
Brief: Biovica Q1 Operating Loss At SEK 12.2 Mln
Brief: Biovica Q4 Operating Loss Widens To SEK 12.2 Mln
Brief: Biovica: DiviTumTKa Shows Strong Capabilities In Malignant Melanoma
Brief: Biovica International: Divitum®Tka Budget Impact Model Results Show Potential For Savings In Cost Of Care
Brief: Biovica International Q3 Operating Loss Widens To SEK 11.1 Million
Brief: Biovica: DiviTumTKA In Early Treatment Resistance Trial
Brief: Biovica International Q2 Operating Loss Widens To SEK 8.3 Mln
Brief: Biovica International Q1 Operating Loss Widens To SEK 8.7 Mln
Brief: Biovica Initiates Collaboration With Mayo Clinic To Study DiviTum